Arsenic trioxide
Information
- Drug Name
- Arsenic trioxide
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Apoptosis induced by ATO is mediated by TNF | MAP2K7 | MAP2K7 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Apoptosis induced by ATO is mediated by TNF | MAP2K7 | MAP2K7 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Combined treatment with EGFR inhibitors and arseni... | EGFR | EGFR UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Reduced ASNA1 expression is associated with signif... | GET3 | GET3 EXPRESSION | Sensitivity | true | MMMP | detail |
| BUBR1 forms the mitotic checkpoint complex (MCC) a... | BUB1B | BUB1B EXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02688140 | Active, not recruiting | Phase 3 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | June 2016 | January 2025 |
| NCT02339740 | Active, not recruiting | Phase 3 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | July 21, 2015 | September 22, 2024 |
| NCT00003934 | Completed | Phase 3 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | June 1999 | |
| NCT00004149 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy | September 1999 | August 2003 |
| NCT00005040 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma | January 2000 | July 2001 |
| NCT00005069 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer | January 2000 | July 2001 |
| NCT00005618 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia | February 2000 | March 2004 |
| NCT02190695 | Completed | Phase 2 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | April 1, 2013 | April 16, 2020 |
| NCT00005795 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia | February 2000 | July 2002 |
| NCT00005999 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer | April 2000 | May 2003 |
| NCT00006008 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | June 2000 | September 2006 |
| NCT00006021 | Completed | Phase 1/Phase 2 | Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma | June 2000 | March 2007 |
| NCT01791894 | Completed | Phase 1/Phase 2 | Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma | April 2013 | November 2015 |
| NCT01470248 | Completed | Phase 2 | Study of Arsenic Trioxide in Small Cell Lung Cancer | August 2011 | January 2016 |
| NCT01428128 | Completed | Phase 2 | Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector | April 2011 | January 2013 |
| NCT00003395 | Completed | Phase 1 | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | April 1998 | March 2000 |
| NCT00008697 | Completed | Phase 1/Phase 2 | Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | November 1998 | April 2002 |
| NCT00009867 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Urothelial Cancer | December 2000 | |
| NCT00016159 | Completed | Phase 2 | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | November 2000 | |
| NCT00866918 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | March 9, 2009 | September 30, 2022 |
| NCT00850304 | Completed | Phase 2 | Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | October 2007 | February 2008 |
| NCT00020111 | Completed | Phase 1 | Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma | March 2000 | |
| NCT00720564 | Completed | Phase 1 | Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma | April 2008 | February 2009 |
| NCT00024258 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | March 2001 | May 2009 |
| NCT00036842 | Completed | Phase 2 | Arsenic Trioxide in Treating Men With Germ Cell Cancer | April 2002 | June 2007 |
| NCT00045565 | Completed | Phase 1 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | October 2002 | |
| NCT00053222 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine | February 2003 | July 2007 |
| NCT00053248 | Completed | Phase 1/Phase 2 | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | October 2002 | June 2005 |
| NCT00671697 | Completed | Phase 1 | Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | May 2008 | May 2011 |
| NCT00661544 | Completed | Phase 1/Phase 2 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | March 2004 | June 2007 |
| NCT00075426 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | November 2002 | July 2005 |
| NCT00081133 | Completed | Phase 1/Phase 2 | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | December 2003 | February 2005 |
| NCT00572065 | Completed | Early Phase 1 | Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis | February 29, 2008 | February 8, 2010 |
| NCT00093366 | Completed | Phase 1/Phase 2 | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes | June 2004 | July 2006 |
| NCT00093483 | Completed | Phase 1 | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 2002 | December 2009 |
| NCT00095771 | Completed | Phase 1 | Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas | November 2004 | January 2011 |
| NCT00551460 | Completed | Phase 2 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | November 15, 2007 | February 5, 2018 |
| NCT00504764 | Completed | Phase 4 | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | July 2007 | October 2014 |
| NCT00482833 | Completed | Phase 3 | Phase III Trial in Acute Promyelocytic Leukemia Patients | August 2007 | October 17, 2019 |
| NCT00124605 | Completed | Phase 1 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | April 2005 | |
| NCT00128596 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery | June 2004 | |
| NCT00185861 | Completed | Phase 1 | Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma | December 2003 | April 2009 |
| NCT00193518 | Completed | Phase 2 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | April 2004 | April 2006 |
| NCT00193544 | Completed | Phase 2 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | March 2002 | January 2009 |
| NCT00454480 | Completed | Phase 2/Phase 3 | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | August 2006 | |
| NCT00201695 | Completed | Phase 2 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | July 2004 | August 2008 |
| NCT00449137 | Completed | Phase 1 | Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment | June 2005 | December 2010 |
| NCT00276601 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | October 2004 | June 2013 |
| NCT00274820 | Completed | Phase 2 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder | October 2005 | October 2007 |
| NCT00258245 | Completed | Phase 1 | Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | May 2005 | April 2008 |
| NCT00274781 | Completed | Phase 2 | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | February 2004 | November 2010 |
| NCT00003630 | Completed | Phase 1 | Arsenic Trioxide in Treating Patients With Advanced Solid Tumors | August 1998 | August 2000 |
| NCT01409161 | Recruiting | Phase 2 | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | October 5, 2011 | December 18, 2025 |
| NCT03503864 | Recruiting | Phase 2 | Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma | January 1, 2019 | December 30, 2028 |
| NCT03751917 | Recruiting | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia | April 14, 2020 | December 2024 | |
| NCT03855371 | Recruiting | Phase 1 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | January 10, 2018 | July 2024 |
| NCT03980665 | Recruiting | Phase 1 | The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART | April 1, 2019 | December 31, 2025 |
| NCT04793919 | Recruiting | Phase 2 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | October 9, 2019 | October 10, 2027 |
| NCT05497310 | Recruiting | Phase 1/Phase 2 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | July 1, 2022 | July 31, 2025 |
| NCT06088030 | Recruiting | Phase 2 | Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer | December 13, 2023 | December 14, 2031 |
| NCT04996030 | Suspended | Phase 1 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | September 17, 2021 | April 2024 |
| NCT00118196 | Terminated | Phase 2 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | April 2005 | August 11, 2006 |
| NCT00225992 | Terminated | Phase 2 | Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) | February 2004 | November 2007 |
| NCT00513305 | Terminated | Phase 3 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | October 2007 | December 2009 |
| NCT00528450 | Terminated | Phase 2 | Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | September 2007 | January 2011 |
| NCT00104806 | Terminated | Phase 2 | Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes | November 2004 | May 2010 |
| NCT00571116 | Terminated | Phase 1 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy | September 2006 | August 2012 |
| NCT00227682 | Terminated | Phase 2 | Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | June 2004 | February 2006 |
| NCT00582400 | Terminated | Phase 2 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | September 2004 | April 2010 |
| NCT00234000 | Terminated | Phase 1 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | February 2007 | |
| NCT00251511 | Terminated | Phase 2 | A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome | August 2004 | May 2007 |
| NCT00061958 | Terminated | Phase 2 | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction | June 2003 | |
| NCT00020969 | Terminated | Phase 2 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | March 2001 | January 2005 |
| NCT00017433 | Terminated | Phase 2 | Arsenic Trioxide in Treating Patients With Multiple Myeloma | January 2001 | January 2005 |
| NCT00017069 | Terminated | Phase 2 | Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma | February 2001 | January 2005 |
| NCT00985530 | Terminated | Phase 1 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | October 2009 | May 2011 |
| NCT01014546 | Terminated | Phase 1 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | April 2010 | February 2015 |
| NCT01184053 | Terminated | Phase 2 | Trisenox® in Women With Metastatic Endometrial Cancer | March 2010 | March 2012 |
| NCT01397734 | Terminated | Phase 1 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) | September 2011 | August 6, 2018 |
| NCT00006220 | Terminated | Phase 1/Phase 2 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | June 1999 | February 2002 |
| NCT00006092 | Terminated | Phase 2 | Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | August 2000 | March 2003 |
| NCT01738360 | Terminated | Phase 2 | Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) | July 2013 | October 2015 |
| NCT00005786 | Terminated | N/A | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | January 2001 | |
| NCT00005595 | Terminated | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | June 2000 | April 2002 |
| NCT00196768 | Unknown status | Phase 4 | Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic | January 2005 | December 2010 |
| NCT02066870 | Unknown status | Phase 1 | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | January 2014 | January 2016 |
| NCT00003885 | Unknown status | Phase 2 | Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma | November 1997 | |
| NCT02899169 | Unknown status | Phase 3 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) | September 1, 2016 | November 1, 2022 |
| NCT02956772 | Unknown status | Phase 2 | Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | November 2016 | November 2020 |
| NCT03031249 | Unknown status | Phase 1/Phase 2 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | February 8, 2017 | December 2022 |
| NCT03381781 | Unknown status | Phase 2 | Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | March 2018 | November 2020 |
| NCT04695223 | Unknown status | Phase 2 | Arsenic Trioxide for Structural p53 Mutations | January 1, 2021 | October 31, 2021 |
| NCT05297123 | Unknown status | Phase 1 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | February 3, 2019 | December 31, 2023 |
| NCT04869475 | Unknown status | Phase 2 | Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | April 20, 2021 | April 30, 2024 |
| NCT00275067 | Unknown status | Phase 1/Phase 2 | Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery | May 2005 | May 2021 |
| NCT00378365 | Unknown status | Phase 3 | Acute Promyelocytic Leukemia 2006 (APL) | October 2006 | September 2016 |
| NCT01835288 | Withdrawn | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2013 | |
| NCT00006090 | Withdrawn | Phase 2 | Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia | June 2000 | October 2001 |
| NCT00085345 | Withdrawn | Phase 2 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | ||
| NCT02699723 | Withdrawn | Early Phase 1 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | December 2020 | September 2021 |
| NCT00504101 | Withdrawn | Phase 1 | Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | June 2007 | June 2011 |
| NCT00006091 | Withdrawn | Phase 2 | Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment | June 19, 2000 | January 2002 |
| NCT00670150 | Withdrawn | Phase 2 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia | May 2010 | August 2010 |
| NCT03377725 | Withdrawn | Phase 3 | Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) | March 20, 2018 | March 31, 2018 |
| NCT00075413 | Withdrawn | Phase 2 | Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | November 2002 | |
| NCT00112879 | Withdrawn | Phase 2 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma |